Evidence of SARS-CoV-2 transcriptional activity in cardiomyocytes of COVID-19 patients without clinical signs of cardiac involvement

Data availability

The raw data are available in Zenodo, at https://dx.doi.org/10.5281/zenodo.3974891.

Patients’ autopsy samples

Autopsies of 6 consecutive non selected patients involved in this study, 5 males and 1 female, aged 54-69 years (average age: 59.5 ± 5.9 years) with a diagnosis of COVID-19, confirmed by CT analysis (Suppl. Fig. 1) and polymerase chain reaction (PCR), were performed in a BSL3 equipped autopsy room at the Unit of Pathology of “ASST Santi Paolo e Carlo” of Milan. Examiners worn clad in all necessary DPIs. Examiners followed the recently published guidelines for performing autopsies and samples with suspected COVID-19 (SIAPEC-IAP).²³ The autopsy examination was performed as soon as possible, by following the recently published recommendations. The period from death to post-mortem autopsy ranged from 1 to 2 hours, documented instrumentally with a continuous and flat ECG for 20 minutes.

All patients had no clinical signs of heart damage and died for SARS-CoV-2-dependent respiratory failure after hospitalization in the Intensive Care Unit. In Table 1 clinical characteristics of all 6 patients involved in this study have been summarized. The autopsy included complete histopathology and virology evaluation. Clinical records were checked for clinical conditions at hospitalization.

mRNA extraction and Digital PCR assay

Tissue samples for RNA were stored in RNAlater (Sigma-Aldrich, Saint Louis, MO, USA). Then, RNA was extracted from tissues by using TRIzol (ThermoFischer Scientific, Waltham, MA, USA) and Hybrid-R columns (GeneAll Biotechnology, Seoul, Korea), following the manufacturer’s instructions.

The RNA quantification was performed by spectrophotometer ND-1000 (NanoDrop®, EuroClone, Pero, Milan, Italy). For viral RNA quantification in myocardial specimens, a one-step chip-based digital PCR was performed on a QuantStudio 3D Digital PCR System platform composed by the QuantStudio 3D Instrument, the Dual Flat Block GeneAmp PCR System 9700 and the QuantStudio 3D Digital PCR Chip Loader (ThermoFischer Scientific, Waltham, MA, USA). TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems, Foster City, CA, USA) was used in combination with TaqMan primers (10006830, 10006831) and FAM probe (10006832) for viral N gene purchased from Integrated DNA Technologies (Integrated DNA Technologies, Coralville, IA, USA), the primers and probe for the N gene were controlled and authorized by the Centers for Disease Control and Prevention, and human RPLP0 gene (Hs99999902_m1) with a VIC probe, as internal amplification control, purchased from Thermo Fisher Scientific. Reverse transcription (RT) was performed at 50°C for 10 minutes, followed by RT inactivation/initial denaturation at 96°C for 5 minutes.

PCR cycling consisted of a denaturation step at 98°C for 30 seconds followed by annealing/extension at 56°C for 1 minute (40 cycles) and a final extension at 60°C for 5 minutes. Analyses were executed with the online version of the QuantStudio 3D AnalysisSuite (ThermoFischer Scientific Cloud, Waltham, MA, USA) following the manufacturer’s instructions.

Western blot analysis

Heart tissues were fragmented by Spectrum™ Bessman Tissue Pulverizers (Fisher Scientific, Hampton, NH, USA) and lysed in cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) supplemented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich, Saint Louis, MO, USA).

Total protein extracts were quantified by BCA Protein Assay (ThermoFischer Scientific, Waltham, MA, USA), then subjected to SDS-PAGE and transferred onto a nitrocellulose membrane. The membranes were blocked for 1 hour at room temperature (RT) in Wash Buffer (Tris Buffer Sulfate 1×, 0.1% Tween 20) supplemented with 5% Bovine Serum Albumine (BSA) and then incubated over-night (O/N) at 4°C with the appropriate primary antibody. Primary antibodies adopted for western blot analysis were specific for ACE2 (R&D System, Minneapolis, MN, USA), SARS-CoV-2 nucleoprotein (Sino Biological, Düsseldorfer, Germany), SARS-CoV-2 spike protein (GeneTex, Irvine, CA, USA), and GAPDH (Santa Cruz Biotechnology, Dallas, TX, USA).

The membranes were incubated with peroxidase-conjugated secondary antibodies (GE Healthcare, Chicago, IL, USA) for 1 hour. Signals were visualized using the Western blotting chemiluminescence substrate LiteUP (EuroClone, Pero, Milan, Italy). Images were acquired with the ChemiDoc system (Bio-Rad Laboratories, Hercules, CA, USA).

Immunostainings and histochemistry

Hearts samples were mapped as follows: full thickness samples from ventricles, atri (2 for each side), and 2 from interventricular septum. Specimens were routinely fixed in 10% buffered formaldehyde for 48 hours as recommended²³ and then 3-μm sections were processed for histopathologic evaluation as well as for immunostainings.

Immunohistochemistry was performed with the automatic immunostainer DAKO OMNIS (DAKO, Glostrup, Denmark), using staining kit with magenta and brown chromogens, routinely applied in our laboratory. The magenta staining was adopted to avoid misinterpretation with lipofuscin granularity typical of cardiomyocyte cytoplasm.

The histochemistry with phosphotungstic acid haematoxylin (PTAH) was performed according to manufacturer’s protocol (BioOptica, Milan, Italy).

Primary antibodies adopted for immunohistochemistry and immunofluorescence were specific for SARS-CoV-2 nucleoprotein (Sino Biological, Düsseldorfer, Germany), SARS-CoV-2 spike protein (GeneTex, Irvine, CA, USA), and α-SARC (AbCam, Cambridge, UK).

As for SARS-CoV-2 nucleoprotein, samples from lungs of patients under study, with immunoreactivity in reactive pneumocytes, macrophages and epithelial respiratory cells were used as controls. Negative controls were also included in the study by omitting the primary antibody. For all the stainings, archival heart and lung tissue samples from patients dead for diseases other than COVID-19 and cardiologic causes were used as controls (Healthy Control).

Immunofluorescence images and analyses were performed by using a Zeiss LSM710 confocal microscope (Carl Zeiss, Oberkochen, Germany).

Except for immunofluorescence, all slides were digitalized with the NanoZoomer S360 Digital slide scanner C13220-01 (Hamamatsu Photonics, Milan, Italy).

RNAscope assays

The RNAScope assays (ACD, Bio-technè, Minneapolis, MN, USA) was performed on 3-μm formalin-fixed paraffin-embedded sections, following Wang et al. published method²⁴, by using specific probes for sense and antisense SARS-CoV-2 RNA spike sequences. Nuclei were counterstained with haematoxylin and the images were acquired by Axiolmager microscope (Carl Zeiss, Oberkochen, Germany).

TUNEL assay

DNA fragmentation associated to necrosis and/or apoptosis was visualized using a terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) detection kit (Roche, Mannheim, Germany). At last, nuclei were counterstained with Hoechst (ThermoFischer Scientific, Waltham, MA, USA) and images were acquired by ApoTomell microscope (Carl Zeiss, Oberkochen, Germany).

Transmission Electron Microscopy

Cardiac tissue samples for ultrastructural analysis were fixed in 2.5% glutaraldehyde in 0.13 M phosphate buffer pH 7.2-7.4 for 2 hours, post-fixed in 1% osmium tetroxide, dehydrated through graded ethanol and propylen oxide, and embedded in epoxy resin. Ultrathin sections of 50 to 60 nm not counterstained were observed with transmission electron microscope Leo 912ab (Carl Zeiss, Oberkochen, Germany).

Ethical approval

Approval was not required (GU n. 72 26/03/2012, page 49).

Patients’ clinical and autoptic features

The patient features reported in Table 1 highlight that all the subjects died for respiratory failure. Supplementary Figures 1 shows a representative result of a pulmonary CT, pathognomonic for COVID-19 disease. Only 1 out of 6 presented a slightly altered cardiac clinical profile, due to a mild hypertrophic LV, likely secondary to hypertension, occurring before the hospitalization for COVID-19 disease. Importantly, all patients did not show alterations of ultrasensitive Troponin I; 2 out of 6 were hypertensive; 2 out of 6 showed hypercholesterolemia, none was diabetic, and 1 presented thyroid dysfunction. All the 6 patients were assisted by mechanical ventilation in Intensive Care Unit for a period ranging from 6 to 21 days.

Concerning autopsy details, hearts ranged in size 410-750 grams (normal: 365 ± 71 grams), with cardiomegaly related to right ventricle dilation, due to lung overload. On cut surface, cardiac tissue was firm, brown, free of lesions, with some delicate areas of myocardiosclerosis in 1 out of 6 patient left ventricles; the coronary system was unremarkable, with no significant stenosis nor thrombosis.

SARS-CoV-2 genome and proteins are present in cardiac samples of COVID-19 patients

We initially confirmed SARS-CoV-2 cardiac tropism in these patients, by examining with chip-based digital PCR the presence of viral RNA in total RNA extracts from heart tissue samples. Viral RNA was found in all COVID-19 heart specimens, but not in the healthy control. The number of copies of SARS-CoV-2 RNA molecules ranged from 4.44 to 5.33 log10(copies/mL) (Figure 1a).

• Download figure
• Open in new tab

Figure 1 RNA and protein of SARS-CoV-2 are present in cardiac samples of COVID-19 patients.

a) Chip-based digital PCR for SARS-CoV-2 N sequence in total RNA extracts from tissues of 3 different patients and different cardiac regions. Raw expression values were expressed as log10(copies/mL). The results are expressed as median and confidence interval (CI 95%). b) Western blot analysis for ACE2, SARS-CoV-2 nucleoprotein, and spike protein on total protein extracts from tissues of 3 put of 6 different patients and different cardiac regions. GAPDH has been adopted as loading control. LV, left ventricle; Septum, interventricular septum; RV, right ventricle.

A Western blot analysis of total protein cardiac autopsy specimen lysates confirmed that the well- known viral gate of host cells ACE2 receptor¹⁷ was expressed in the cardiac tissue²⁰. Similar levels of expression were found in different cardiac districts and, of note, independently on COVID-19. Furthermore, we showed, for the first time, that SARS-CoV-2 viral proteins are detectable in COVID-19 patient hearts, while no traces have been found in the healthy control. In detail, nucleoprotein and spike protein were expressed at different levels in the analysed patients (Figure 1b), raising the hypothesis that the viral genome is actively transcribed into cardiomyocytes.

SARS-CoV-2 is localized in cardiomyocytes of COVID-19 patients in terms of viral proteins and RNA

The light microscopy analyses performed firstly allowed us to define all COVID-19 cases as similar by microscopic aspects. In details, the immunohistochemical analyses confirmed positivity for COVID-19 in left ventricular cardiac samples for SARS-CoV-2 nucleoprotein and spike protein (Figure 2a, b). Of note, viral proteins were found within cardiomyocytes cell body, and more specifically, in cytosolic are of lipofuscin (Suppl. Fig. 2a). This finding was confirmed by immunofluorescence co-staining of viral nucleoprotein with SARC-positive cells (Figure 2c).

• Download figure
• Open in new tab

Figure 2 SARS-CoV-2 proteins are detectable in cardiomyocytes of COVID-19 patients.

a-b) Representative images of immunohistochemistry assays on 3μm-slides of formalin-fixed paraffin-embedded left ventricle specimens from healthy control (Healthy Ctrl, left panels) and COVID-19 patients (COVID-19, central and right panels) for SARS-CoV-2 nucleoprotein (a, in red) and spike protein (b, in brown). c) Representative images of immunofluorescence assay on 3μm-slides of formalin-fixed paraffin-embedded left ventricle specimens from healthy control (Healthy Ctrl, left panels) and COVID-19 patients (COVID-19, central and right panels) for SARS-CoV-2 nucleoprotein (green) and sarcomeric α-actin (α-SARC, red). Nuclei have been stained by Hoechst (blue). Magnification as scale bars.

In order to determine the presence of SARS-CoV-2 as transcriptionally active virus into cardiomyocytes, we performed the RNAScope assay (Figure 3).²⁴ In detail, this in situ hybridization was performed by use of two different probes, recognising the spike protein RNA, sense (Figure 3a) and antisense (Figure 3b), allowing distinction of the viral RNA genome from its transcript. Signals were obtained with both probes in cardiomyocytes of COVID-19 patients only, but the most abundant staining resulted from the probe detecting the actively transcribed virus (Figure 3b).

• Download figure
• Open in new tab

Figure 3 SARS-CoV-2 sense and antisense RNA are localized into cardiomyocytes of COVID-19 patients.

a-b) Representative images of spatially resolved viral RNA detection by RNAScope assay on 3μm- slides of formalin-fixed paraffin-embedded left ventricle specimens from healthy control (Healthy Ctrl, left panels) and COVID-19 patients (COVID-19, central and right panels) for SARS-CoV-2 sense (a) and antisense (b) probes for spike protein RNA sequences. Fast Red dots indicate viral RNA presence (white arrows). Nuclei have been counterstained with haematoxylin. Magnification as scale bars.

Cardiomyocytes containing SARS-CoV-2 do not show cell death sign, but display intracellular alterations

In Figure 4, the immunohistochemistry for SARS-CoV-2 nucleoprotein and PTAH staining, performed on consecutive heart sections, highlighted several microscopic scenarios. Not all the cardiomyocytes contain the virus, and among those positive for the viral nucleoprotein we found living and unaltered cells (Figure 4a). Nonetheless, we appreciated, through PTAH staining, isolated or grouped cardiomyocytes showing atypical degenerative aspects, such as increased cell volumes with intracellular oedema, together with rarefied, disarranged, disrupted, and plurifocally clumped myofibrils (Figure 4b).

• Download figure
• Open in new tab

Figure 4 Several cardiomyocytes containing SARS-CoV-2 nucleoprotein display intracellular alterations, but not cell death signs.

a-b) Representative images on consecutive slides of immunohistochemistry assay for SARS-CoV-2 nucleoprotein (a) and PTAH staining (b, sarcomere structures in violet/blue), performed on left ventricle specimens from COVID-19 patients. Black arrows indicate strongly immunoreactive interstitial cells for SARS-CoV-2 nucleoprotein (in red), with a morphology consistent with macrophages. c) Representative images of TUNEL assay on 3μm-slides of formalin-fixed paraffin-embedded left ventricle specimens from COVID-19 patients. Damaged DNA is marked in green, nuclei have been counterstained with Hoechst (blue). Magnification as scale bars.

In order to investigate whether these interesting features, concerning cardiac cell alterations, may be linked to apoptotic/necrotic processes activation, we performed TUNEL assay on all the subject samples and we detected no cell death signs, except for the peripheral sample regions (Figure 4c, d).

Vascular modifications were unremarkable; no endothelial viral cytopathic effects nor endotheliitis was here documented. Furthermore, a low grade of inflammatory infiltrates was observed in cardiac tissue, especially in sub-pericardiac regions without a specific distribution (Suppl. Fig. 2b). Sporadic interstitial macrophages displayed a strong immunoreactivity for SARS-CoV-2 nucleoprotein (Suppl. Fig. 2c).

The investigation by electron microscopy confirmed the previously obtained evidence on the SARS- CoV-2 presence in cardiomyocytes. Indeed, single and/or grouped spherical particles about ~130 nm in diameter, with electron dense periphery characterized by crown-shaped small external projections and a morphology compatible to SARS-CoV-2 were clearly visible in the intracellular space between sarcomeres and sarcolemma of cardiomyocytes (arrows, Figure 5a, b).

• Download figure
• Open in new tab

Figure 5 SARS-CoV-2 virions are localized within both normal and altered cardiomyocytes of COVID-19 patients.

a, c, e) Electron micrograph showing cardiomyocytes containing viral particles (white arrows), compatible with crown-shaped SARS-CoV-2. The viral particle diameter (a) is of ~116 nm. b, d, f) High magnifications of red squared areas of panel a, c, and e, respectively. In all panels, asterisks indicate normal mitochondrial and sarcomere structures, while cytoplasmic and sarcomere alterations are indicated with hashtags.

As for immunohistochemistry and histology assays, the cardiomyocyte phenotype is not univocal: while some cardiomyocyte hosting SARS-CoV-2 did not present any evident abnormality in terms of cellular structures, other cardiac cells presented peculiar degenerative features, such as excessive intracellular area between sarcolemma and sarcomere structure (Figure 5c, d) and abnormal, disrupted and clumped myofibrils (Figure 5e, f). Regarding the former alteration, this cardiomyocyte swelling (Figure 5c, hashtag) may microscopically explain the cardiac oedema, previously observed in histological examinations. Noteworthy, the sarcomere rupture occurs in co-localization of SARS-CoV-2 viral particle (Figure 5f, hashtag).

Although the microscopy investigation was compatible with cardiomyocyte damage, it is important to highlight that, at ultrastructural level, the sarcolemma and mitochondria resulted unaltered and structurally undamaged (Figure 5a, c, e, asterisks), thus not suggestive of cardiomyocyte death.